Transcriptomic profiling of HepG2 cells under apilimod treatment
Hepatocellular carcinoma (HCC) remains a leading global cause of cancer death, largely due to treatment resistance and recurrence. While targeting PIKFYVE represents a promising strategy for cancer therapy, the anti-HCC efficacy of its inhibition and the underlying resistance mechanisms require further exploration. This study therefore aimed to investigate the anti-HCC effects of apilimod (APD, a PIKFYVE inhibitor) and determine its resistance mechanisms in HCC.